A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists

Completed

• Conditions: Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)
• Interventions: Other: No treatment given

• Registration Number: NCT06589791
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This is a survey-based study with the objective to understand the awareness, perceptions and potential clinical management patterns among Chinese cardiologists and nephrologists towards the role of systemic inflammation in patients with ASCVD and CKD in real-world clinical setting.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-09-06
• Study First Submitted QC: 2024-09-06
• Study Start: 2024-09-09
• Study First Posted: 2024-09-19
• Primary Completion: 2024-12-05
• Study Completion: 2024-12-05
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-06
• Last Update Posted: 2025-01-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

• Work in cardiology, internal medicine, or nephrology department
• Specialize in one of the following: coronary interventional cardiology, HF, general cardiology, preventive cardiology, cardiac rehabilitation or nephrology
• Practice at consultant level for 3+ years after standardized training for resident physicians or 3+ years' working experience as a specialist
• Manage at least 20 adult patients with ASCVD and CKD (not dialysis-only) every month

Exclusion Criteria

• Unwilling to provide informed consent
• Insufficient number of patients with ASCVD and CKD
• Do not fulfil inclusion criteria.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Health care professionals	No treatment given	Cardiologists and nephrologists in China

Primary Outcome Measures

Name	Time	Method
Health care professional's perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD	At the time of survey response (Day 1)	Multi-select from a defined list; Single-select from a defined list; Numerical; 7-point Likert scale for measurement of agreement to different statements from 1 "strongly disagree" to 7 "strongly agree"

Trial Locations

Locations (1)

Novo Nordisk Shanghai Pharmaceuticals Co., Ltd; 🇨🇳 Shanghai, China